Connection
Nahed El-Hassan to Cost-Benefit Analysis
This is a "connection" page, showing publications Nahed El-Hassan has written about Cost-Benefit Analysis.
|
|
Connection Strength |
|
|
|
|
|
0.063 |
|
|
|
-
Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006 Oct; 160(10):1070-6.
Score: 0.063